The FDA approved ER-100, a cellular rejuvenation therapy, for human clinical trials — the first time this type of reverse-aging drug is being tested in people. The initial trial targets age-related blindness and optic nerve damage, though researchers see potential applications across other age-related diseases. This is the result of years of cellular reprogramming research backed by longevity-focused tech investors, but scientists emphasize don't expect consumer anti-aging pills anytime soon — this is early-stage clinical work.